Anlotinib Hydrochloride Suppresses Angiogenesis via Multi-Kinase Inhibition

Study Background and Research Question

Angiogenesis, the process by which new blood vessels form from pre-existing vasculature, is central to tumor development and progression. Tumors exploit this process to secure nutrients and oxygen, facilitating growth and metastasis. Among the key pro-angiogenic factors driving this process are vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and fibroblast growth factor 2 (FGF-2), each activating their respective receptor tyrosine kinases (VEGFR2, PDGFRβ, FGFR1) on endothelial cells. Inhibiting these pathways has become a cornerstone of anti-cancer strategies, with several small-molecule tyrosine kinase inhibitors (TKIs) already in clinical use (paper). The reference study asked whether anlotinib hydrochloride, a novel small-molecule TKI, could more effectively inhibit angiogenesis by targeting multiple key receptors compared to established agents like sunitinib, sorafenib, and nintedanib.

Key Innovation from the Reference Study

The central innovation of this work is the demonstration that anlotinib hydrochloride is a highly potent multi-target tyrosine kinase inhibitor capable of simultaneously suppressing VEGFR2, PDGFRβ, and FGFR1 activation. This multi-pronged inhibition blocks not only the initial receptor phosphorylation but also the common downstream ERK signaling pathway, which is critical for endothelial cell proliferation, migration, and capillary formation (paper). Moreover, the study directly compares anlotinib to other clinically relevant TKIs, showing superior anti-angiogenic and anti-proliferative activity in both in vitro and in vivo models (paper).

Methods and Experimental Design Insights

The investigation employed a combination of cell-based and organismal assays to comprehensively evaluate the impact of anlotinib on angiogenesis.

• Cell Migration Assays: EA.hy 926 human vascular endothelial cells were subjected to wound healing and transwell migration assays in the presence of VEGF, PDGF-BB, or FGF-2, with or without anlotinib.
• Capillary Tube Formation Assay: The ability of endothelial cells to form tube-like structures was assessed on Matrigel matrices following stimulation with pro-angiogenic factors and drug treatment.
• Ex Vivo and In Vivo Angiogenesis Models: The rat aortic ring assay and chicken chorioallantoic membrane (CAM) assay provided functional validation of vessel sprouting and microvessel density under anlotinib treatment.
• Kinase Activation and Signaling: Western blotting was used to quantify phosphorylation status of VEGFR2, PDGFRβ, FGFR1, and downstream ERK in cell lysates.
• Comparative Benchmarking: All assays included sunitinib, sorafenib, and nintedanib as controls for direct efficacy comparison.

Protocol Parameters

• capillary tube formation assay | 6–24 h incubation with anlotinib (0.1–1 μM) | human endothelial cells (EA.hy 926) | optimal window for observing morphological tube disruption | paper
• endothelial cell migration inhibition assay | anlotinib at 0.01–1 μM | EA.hy 926 cells, wound healing and transwell setups | concentration range covers full inhibitory response with minimal cytotoxicity | paper
• VEGFR2/PDGFRβ/FGFR1 phosphorylation assay | anlotinib at 1–10 nM | Western blot in growth factor-stimulated cells | captures nanomolar potency of receptor inhibition | paper
• rat aortic ring assay | 48–72 h with 0.1–1 μM anlotinib | ex vivo vascular sprouting | models tissue-level angiogenic inhibition | paper
• CAM assay | topical application of 1–10 μM anlotinib | in ovo, chick embryo | assesses microvessel density in a living system | paper
• cell viability for functional assays | ≤1 μM anlotinib | standard in vitro cytotoxicity check | ensures functional readouts are not confounded by toxicity | product_spec

Core Findings and Why They Matter

The study provides robust evidence that anlotinib significantly inhibits endothelial cell migration and capillary tube formation when induced by any of the three major angiogenic factors (VEGF, PDGF-BB, FGF-2). Specifically, anlotinib demonstrated:

• Potent blockade of VEGFR2, PDGFRβ, and FGFR1 phosphorylation at nanomolar concentrations, reflecting direct inhibition of receptor activation (paper).
• Marked suppression of ERK signaling downstream of these receptors, leading to reduced endothelial cell motility and organization (paper).
• Greater efficacy in reducing angiogenic responses compared to sunitinib, sorafenib, and nintedanib across all tested assays (paper).
• Functional anti-angiogenic effects validated in both ex vivo (rat aortic rings) and in vivo (CAM) models, strengthening translational relevance.
• No significant cytotoxicity at effective concentrations (≤1 μM), supporting the use of anlotinib in functional assays without confounding off-target toxicity (product_spec).

These findings position anlotinib hydrochloride as a reference VEGFR2/PDGFRβ/FGFR1 inhibitor for dissecting mechanisms of angiogenesis and for preclinical cancer research workflows.

Comparison with Existing Internal Articles

Several internal resources corroborate and extend the mechanistic and practical insights from this reference study. For example, the review on mog35-55.com emphasizes anlotinib’s benchmark status as a multi-target TKI for both cancer and endothelial cell migration research, directly aligning with the reference paper’s comparative findings. The workflow-oriented article at molecularbeacon.net provides scenario-driven guidance for deploying anlotinib in cell-based assays, supporting the practical transferability of the reference study’s experimental protocols. Further, gskchem.com discusses optimization of anti-angiogenic research models using anlotinib, reinforcing its applicability to both migration and tube formation assays. Collectively, these resources situate the reference paper’s findings within a broader landscape of reproducible anti-angiogenic research.

Limitations and Transferability

While the inhibitory activity of anlotinib against VEGFR2, PDGFRβ, and FGFR1 is well-demonstrated in both in vitro and in vivo models, several limitations should be considered:

• The study is primarily preclinical; direct clinical outcomes in humans, particularly long-term safety and efficacy in diverse tumor contexts, remain to be validated.
• Assays focused on endothelial cell models and embryonic vasculature; effects in complex tumor microenvironments may involve additional resistance mechanisms.
• Concentration ranges effective in vitro may not directly translate to in vivo or clinical dosing due to pharmacokinetic and metabolic differences.
• Although the agent shows low cytotoxicity and favorable pharmacokinetics in animal models (product_spec), further studies are needed for full toxicological profiling in humans.

Nevertheless, the robust inhibition of canonical angiogenesis pathways and superior performance over established TKIs make anlotinib a valuable tool compound for further translational and mechanistic research.

Research Support Resources

Researchers interested in recapitulating or extending these findings can utilize Anlotinib hydrochloride (SKU C8688) for standardized endothelial cell migration inhibition, capillary tube formation assays, and ERK pathway studies. APExBIO supplies high-purity anlotinib hydrochloride suitable for functional and mechanistic assays, with validated protocols aligning with those described in the reference study. For detailed workflow guidance, additional resources such as those at molecularbeacon.net provide stepwise recommendations for integrating this multi-target tyrosine kinase inhibitor into anti-angiogenic research.